EMPOWER-HER for metastatic HER2+ Breast Cancer - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician?s choice chemotherapy compared to trastuzumab in combination with physician?s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Principal Investigator
Rani Bansal, MD
Medical Oncologist
Protocol Number
IRB:
PRO00116169
NCT:
NCT06435429
Phase
Phase III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment